Immune cell therapy shows promise for advanced melanoma – does adding radiation help?
NCT ID NCT01319565
First seen Jan 05, 2026 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study tested an experimental treatment for metastatic melanoma using a patient's own immune cells (tumor-infiltrating lymphocytes) grown in a lab and given back along with high-dose IL-2. Before the cell infusion, all patients received chemotherapy to suppress their immune system, and half also got total body irradiation. The goal was to see if adding radiation helped the cells work better. The trial enrolled 102 adults with metastatic melanoma and measured tumor shrinkage and survival.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC MELANOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Tumor-infiltrating lymphocytes (TILs), aldesleukin (IL-2), cyclophosphamide, fludarabine, and total body irradiation
What this could lead to
If successful, this approach could improve tumor shrinkage and survival for people with metastatic melanoma by boosting the immune system's ability to attack cancer.
What could go wrong
This is a phase 2 trial with 102 participants, so results are still preliminary. Adding total body irradiation increases side effects like immune suppression and infection risk, and may not improve outcomes over chemotherapy alone.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.